ArticleCancer chemotherapy and pharmacology2024
Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Mototsugu Oya et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.